Treatment Options
The UroLift® System is a proven option for patients looking for an alternative to drugs or major surgery. It is transurethral BPH treatment that does not require ongoing medication, heating, cutting or removal of the prostate tissue.
The UroLift® System offers a proven treatment with minimal risk of side effects while preserving sexual function*1.
What Are the Treatment Options?
-
Non-Invasive
Medication & Monitoring
Alpha-blockers can help relax the muscles around the neck of the bladder to aid urination, while alpha-reductase inhibitors can help to shrink the prostate.
-
Minimally Invasive
Prostatic Urethral Lift (PUL) – Using the UroLift® System
A straightforward procedure that deploys small implants to lift and compress the sides of the prostate to make the urethra wider and increase the flow of urine.
-
Thermotherapies & Lasers
An array of semi-invasive procedures involving the removal of prostate tissue via heat, steam, or lasers to relieve symptoms.
-
Most Invasive
Surgery
Transurethral resection of the prostate (TURP) involves using a superheated thin metal band to cut and remove prostate tissue. In severe cases with very large prostate or complications, open surgery is needed to reach the prostate.
Preservation of Sexual Function
As PUL does not remove or damage prostate tissue, it can better preserve sexual function.
In a global survey of over 13,000 men aged 40-80 across 29 countries, nearly 50% rated sex as being very to extremely important.7 Erectile dysfunction contributes to anxiety, depression, loss of self-esteem and diminished quality of life.8 In choosing a BPH treatment, it is important to consider the impact that ejaculatory and erectile dysfunction have on patient satisfaction.
Low Retreatment Rate
The rate of surgical intervention for failure to cure with the UroLift® System remains low for a BPH procedure, with approximately 13.6% over five years or about 2-3% per year.1 Over the first postoperative year, no additional surgical intervention was required for bladder neck contracture, bleeding, or stress incontinence in the pivotal study on UroLift® System.5
Sign Up for Updates on the UroLift® System
*No instances of new onset, sustained erectile or ejaculatory dysfunction in the LIFT pivotal study
References
1.
Roehrborn et al. Can J Urol 2017
2.
AUA Guidelines 2003
3.
Mayo Clinic, Patient Care & Health Information, Diseases & Conditions, Benign prostatic hyperplasia (BPH). Accessed 1 Dec 2021
4.
BAUS Leaflet No: 21/179, 2021
5.
Roehrborn, J Urology 2013
6.
McVary, J Urol 2016
7.
Laumann, Arch Sex Beh April 2006
8.
Carbone, Int J Impot Res 2003
Healthcare Professional Confirmation
The information on the page you are about to enter is intended for Healthcare Professionals
only.
By clicking the box below, you confirm that you are a Healthcare Professional.